HPV Vaccine May Reduce Cervical Cancer Rates in Developing Countries

Human papillomavirus (HPV) is a set of over 150 viruses; know as papilloma viruses, which encourages a certain type of skin growths. Human papilloma viruses (HPV) are often connected to certain kind of cancer, also known as, carcinogenic HPVs or “high-risk," oncogenic.

Out of 150 types of HPV, 40 types of HPV are contagious, and can be transmitted from person to person during sexual interaction. The transmission of HPV can take place by genitals or oral, even if usually HPV’s is passed on sexually. It is studied that several Human papilloma virus (HPV) appear without any indications and goes away without any treatment.

The major cause of cervical cancer is high-risk HVP infection. More or less all the women have HPV infection, at some point of time, but only few develop into cervical cancer. Immune system, nearly in all the women, is suppresses or reduces HPV. Only a persistent HPV infection leads to the development of cervical cancer.

As per a study, giving human papilloma virus (HPV) vaccine dose for a longer period of time may establish an effectual way to formulate the vaccine to be obtainable to more and more women’s in the underprivileged nations.

According to the researcher, different schedules of dosing vaccine where used to conclude the treatment in the developing country.

The WorldHealth Organization (WHO) has accepted this programmatic limitation that should be considered to be initiated in the national Human papilloma virus (HPV) vaccination programs. Neuzil's team has announced that, delivering Human papilloma virus (HPV) vaccine in flexible timetable, will lets countries to  reduces the cost and increase the availability of vaccination  programs.